Decarbonising Respiratory Care: The Impact of a Low‐Carbon Salbutamol Pressurised Metered‐Dose Inhalers
Allergy · 2026-07 · 81 (7) · 2357-2365
DOI: 10.1111/all.70141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 06.11.2025. Verfasst von James King und 7 weiteren Autor:innen. Beteiligte Einrichtung: Environment, Health, Safety and Sustainability, GSK, London, UK. Hauptthemen laut MEDLINE: Albuterol, Metered Dose Inhalers, Greenhouse Gases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.
Abstract (Originalsprache)
Background
Rapid reductions in greenhouse gas (GHG) emissions are vital to combat climate change. Healthcare systems contribute ~5% of global GHG emissions, with pressurised metered‐dose inhalers (pMDIs) a significant contributor owing to their hydrofluorocarbon propellants. This study compared GHG emissions of a salbutamol pMDI using a low‐carbon propellant in clinical development, hydrofluoroalkane (HFA)‐152a, against current salbutamol inhalers.
Methods
Three ‘cradle‐to‐grave’ lifecycle analyses compared GHG emissions of salbutamol pMDIs with HFA‐152a and HFA‐134a, and salbutamol dry‐powder inhaler (DPI). Over 600 individual emission factors were calculated from > 2000 data points, and categorised into Active Pharmaceutical Ingredients Manufacture, Micronisation, Device, Formulation/Packaging, Use, Distribution and End‐of‐Life stages. 2023 manufacturing and supply data were collected from Algeria, Australia, Canada, France, Poland, Romania and Saudi Arabia. Carbon footprints were independently verified by the Carbon Trust.
Results
Mean total carbon footprint per salbutamol inhaler (based on 100‐year global warming potential [GWP100]) was 26.91, 2.06 and 0.69 kgCO 2 e for HFA‐134a pMDI, HFA‐152a pMDI and DPI, respectively. This equated to a 92% reduction in total emissions for HFA‐152a versus HFA‐134a. Most pMDI emissions came from the Use stage (HFA‐134a: 21.48 kgCO 2 e; HFA‐152a: 1.45 kgCO 2 e). Per actuation, emissions were 135, 10 and 11 gCO 2 e, respectively. For each pMDI, GHG emissions were similar across countries.
Conclusions
The low‐GWP propellant, HFA‐152a is expected to achieve > 90% reduction in the carbon footprint of salbutamol pMDI versus the currently used HFA‐134a. The development of salbutamol pMDI with HFA‐152a is a crucial step towards ensuring future patient access to salbutamol in a pMDI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Environment, Health, Safety and Sustainability, GSK, London, UK.
- University of Manchester, Manchester, UK.
- South Texas Veterans Health Care System, University of Texas Health San Antonio, San Antonio, Texas, USA.
- Department of Respiratory Medicine, East and North Hertfordshire NHS Trust, Stevenage, UK.
- Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
- GSK, General Medicines, Mumbai, India.
ORCID-Profile: James King, Ashley Woodcock, Antonio Anzueto, Alexander J K Wilkinson, Christer Janson, Richard Henderson, Maximilian Plank
Förderung
- GSK
- GlaxoSmithKline
Zitieren
APA
King, J., Woodcock, A., Anzueto, A., Wilkinson, A. J. K., Janson, C., Henderson, R., Fulmali, S., & Plank, M. (2026). Decarbonising Respiratory Care: The Impact of a Low‐Carbon Salbutamol Pressurised Metered‐Dose Inhalers. Allergy, 81(7), 2357-2365. https://doi.org/10.1111/all.70141
Vancouver
King J, Woodcock A, Anzueto A, Wilkinson AJK, Janson C, Henderson R, et al. Decarbonising Respiratory Care: The Impact of a Low‐Carbon Salbutamol Pressurised Metered‐Dose Inhalers. Allergy. 2026;81(7):2357-2365. doi:10.1111/all.70141
BibTeX
@article{King2026,
author = {King, James and Woodcock, Ashley and Anzueto, Antonio and Wilkinson, Alexander J K and Janson, Christer and Henderson, Richard and Fulmali, Sourabh and Plank, Maximilian},
title = {Decarbonising Respiratory Care: The Impact of a Low‐Carbon Salbutamol Pressurised Metered‐Dose Inhalers},
journal = {Allergy},
year = {2026},
volume = {81},
number = {7},
pages = {2357--2365},
doi = {10.1111/all.70141}
}
EUVIMED